Key Highlights
- Dean Gregory appointed to Cerus’ Board of Directors.
- 30+ years of experience in blood transfusion and cell therapy.
- Former President of Global Commercial Operations, Med Tech at Fresenius Kabi.
- Expert in commercialization, product development, and supply chain.
- Will contribute to expanding INTERCEPT Blood System’s reach and manufacturing capacity.
Source: Business Wire
Notable Quotes
- “Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, having led the commercial organization of one of the major suppliers for blood centers and hospitals in this space.” — Daniel Swisher, Chair of the Board at Cerus Corporation
- “I have a long-standing connection to Cerus and the INTERCEPT Blood System, and I am thrilled to be able to contribute in this new way.” — Dean Gregory, Member of the Board of Directors at Cerus Corporation
SoHC's Take
The appointment of Dean Gregory to Cerus Corporation’s Board of Directors is a strategic move that leverages his extensive experience in the global blood transfusion and cell therapy industry. His proven track record in commercialization and operational leadership at top firms like Fresenius Kabi and Baxter International positions him as a valuable asset for Cerus. This move is likely to bolster Cerus’ efforts in expanding the reach and manufacturing capacity of the INTERCEPT Blood System, aligning with the company’s mission to enhance patient access to safe blood products globally.
